Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes

Table 1 Presence of different immune cell types in the pancreatic islets

Cell types	Healthy control (n/mm²)	Anti-TCR and anti-IL-6 (n/mm²)	Anti-TCR and anti-IL-17A (n/mm²)	Anti-TCR, anti-IL-6 and anti-IL-17A (n/mm²)	Diabetic control (n/mm²)
CD4 T cells	0 ± 0	0 ± 0	1 ± 0*	0 ± 0**	4 ± 0
CD8 T cells	0 ± 0	0 ± 0**	5 ± 1**	0 ± 0**	26 ± 3
γ,δ T cells	0 ± 0	2 ± 1	0 ± 0**	0 ± 0**	3 ± 1
CD68 MØ	3 ± 1	7 ± 1**	8 ± 0**	3 ± 1**	34 ± 4
Others	0 ± 0	0 ± 0	0 ± 0	0 ± 0	8 ± 2

Quantification of the different immune cell types in the pancreatic islet after immunostaining for CD4, CD8, γ,δ T cells and CD68 macrophages 60 days after the end of different anti-TCR combination therapies with anti-IL-6 or anti-IL-17A alone or in triple fashion in the LEW.1AR1-iddm rats. The quantitative analysis of the frequency in the immune cells was performed in the pancreases of the successfully treated rats in all groups (a total of 50 to 80 islets in each group. *p < 0.05, **p < 0.01 by ANOVA followed by Dunnett’s test for all successful therapies against the diabetic controls. Numbers of pancreases analysed as given in Fig. 1

ISSN: 1741-7015